KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Moderna (MRNA) Accumulated Depreciation & Amortization (2016 - 2025)

Moderna (MRNA) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $211.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 14.05% to $211.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $211.0 million, a 14.05% increase, with the full-year FY2025 number at $211.0 million, up 14.05% from a year prior.
  • Accumulated Depreciation & Amortization was $211.0 million for Q4 2025 at Moderna, up from $51.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $617.0 million in Q4 2023 to a low of $15.0 million in Q1 2021.
  • A 5-year average of $148.4 million and a median of $81.5 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 1825.0% in 2021, then plummeted 87.68% in 2024.
  • Moderna's Accumulated Depreciation & Amortization stood at $232.0 million in 2021, then skyrocketed by 50.0% to $348.0 million in 2022, then soared by 77.3% to $617.0 million in 2023, then plummeted by 70.02% to $185.0 million in 2024, then rose by 14.05% to $211.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Accumulated Depreciation & Amortization are $211.0 million (Q4 2025), $51.0 million (Q3 2025), and $56.0 million (Q2 2025).